These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

625 related items for PubMed ID: 23543481

  • 1. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A, Cozzolino M, Adragao T, Di Iorio B, Russo D.
    J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Use of phosphate binders in chronic kidney disease.
    Ketteler M, Biggar PH.
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L, Bernard LM, Elder GJ.
    Clin J Am Soc Nephrol; 2016 Feb 05; 11(2):232-44. PubMed ID: 26668024
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C, Roe K, Lehman E, Verma N.
    Nephron Clin Pract; 2013 Feb 05; 123(1-2):61-6. PubMed ID: 23774446
    [Abstract] [Full Text] [Related]

  • 10. Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes.
    Bhandari SK, Liu IA, Kujubu DA, Huynh T, Behayaa H, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ, Sim JJ.
    Am J Nephrol; 2017 Feb 05; 45(5):431-441. PubMed ID: 28445887
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ, Shaheen FA.
    Saudi J Kidney Dis Transpl; 2010 Jan 05; 21(1):93-101. PubMed ID: 20061700
    [Abstract] [Full Text] [Related]

  • 13. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Jan 05; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 14. The challenge of controlling phosphorus in chronic kidney disease.
    Cannata-Andía JB, Martin KJ.
    Nephrol Dial Transplant; 2016 Apr 05; 31(4):541-7. PubMed ID: 25770169
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hyperphosphatemia and phosphate binders: effectiveness and safety.
    Kalaitzidis RG, Elisaf MS.
    Curr Med Res Opin; 2014 Jan 05; 30(1):109-12. PubMed ID: 24007207
    [Abstract] [Full Text] [Related]

  • 17. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
    Scialla JJ, Kendrick J, Uribarri J, Kovesdy CP, Gutiérrez OM, Jimenez EY, Kramer HJ.
    Am J Kidney Dis; 2021 Jan 05; 77(1):132-141. PubMed ID: 32771650
    [Abstract] [Full Text] [Related]

  • 18. Phosphate management in chronic kidney disease.
    Bhan I.
    Curr Opin Nephrol Hypertens; 2014 Mar 05; 23(2):174-9. PubMed ID: 24445424
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.